- $696.47m
- $1.83bn
- 20
- 41
- 49
- 30
Annual income statement for Prokidney, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 27 | 55.1 | 153 | 152 |
| Operating Profit | -27 | -55.1 | -153 | -152 |
| Total Net Non Operating Interest Income / Expense | ||||
| Net Income Before Taxes | -27 | -55.1 | -147 | -129 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -26.7 | -55.1 | -148 | -135 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | -26.7 | -55.1 | -108 | -35.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -26.7 | -55.1 | -108 | -35.5 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.435 | -0.896 | -1.76 | -0.575 |
| Dividends per Share |